Clinical Trials Browser

elacestrant × Clear all

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06638307 2026-04-13

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1 Recruiting

Advanced Breast Cancer

NCT07198724 2026-04-09

ERADICATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT05386108 2026-04-06

ELECTRA

Phase 1/2 Recruiting

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

Advanced Breast Cancer

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06923527 2026-03-27

Circulating Tumor DNA

Phase 2 Recruiting

ER+ Breast Cancer

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT07467772 2026-03-12

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Phase 2 Not yet recruiting

GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07395336 2026-02-09

COMBINE-01

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

Phase 2 Recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT06691035 2025-12-04

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06201234 2025-12-01

ELEMENT

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07159451 2025-12-01

POP-ELA

Phase 2 Recruiting

Breast Neoplasms

NCT07242352 2025-11-21

ADAPTela

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 2 FDA

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

Phase 3 Recruiting

Breast Neoplasms

NCT05596409 2025-06-05

ELCIN

Phase 2 Active not recruiting

Breast Neoplasms

NCT07005882 2025-06-05

HELP

Phase 2 Not yet recruiting

Breast Cancer Patients

NCT05982093 2025-05-22

SOLTI-2104

Phase 2 Active not recruiting

Breast Neoplasms

NCT05618613 2025-05-09

ELONA

Phase 1/2 Terminated

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

ESR1 Gene Mutation

NCT04797728 2022-10-26

ELIPSE

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Phase 1 Completed

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms